ARMAGEN TECHNOLOGIES, INC.
Biotech · Acquired
AGT-184, a genetically engineered fusion protein combining SGSH enzyme with a blood-brain barrier-penetrating monoclonal antibody for treating brain lysosomal storage disease.
armagen.com →- Grants
- $1.6M
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 4 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | $1,033,433 | |
| Federal grant | Department of Health and Human Services · Phase II · Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome | $612,428 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1712 | NEUROGT INC | — | — |
| 1713 | Lila Sciences | — | — |
| 1714 | ARC Biotechnology LLC | — | — |
| 1715 | ARMAGEN TECHNOLOGIES, INC. | — | — |
| 1716 | Metallomix, Inc | — | $2.1M |
| 1717 | Mission Therapeutics | — | — |
| 1718 | Curve Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods Related To Structures That Cross The Blood Brain Barriergranted
- Methods And Compositions For Increasing Alpha-l-iduronidase Activity In The Cnsgranted
- Methods And Compositions For Increasing Arylsulfatase A Activity In The Cnsgranted
- Methods and Compositions for Increasing Arylsulfatase A Activity in the CNSgranted
- Compositions And Methods Related To Structures That Cross The Blood Brain Barrierapplication
- Methods And Compositions For Increasing Arylsulfatase A Activity In The Cnsapplication
- Fusion Proteins For Delivery Of Erythropoietin To The Cnsapplication
- Methods And Compositions For Increasing Iduronate 2-SULFATASE Activity In The Cnsapplication
- Compositions And Methods For Blood-brain Barrier Delivery Of Igg-decoy Receptor Fusion Proteinsapplication
- Fusion Proteins For Delivery Of Gdnf To The Cnsapplication
- Methods And Compositions For Increasing Alpha-iduronidase Activity In The Cnsapplication
- Agents For Blood-brain Barrier Deliveryapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.